NEXI - NexImmune Announces Presentations at The Society for Immunotherapy of Cancer's 38th Annual Meeting | Benzinga
GAITHERSBURG, Md., Oct. 19, 2023 (GLOBE NEWSWIRE) -- NexImmune, Inc. a biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells in oncology, autoimmune and infectious diseases, today announced that three abstracts have been accepted for poster presentation at the upcoming Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting in San Diego, CA , being held November 1-5, 2023.
"We are pleased that abstracts highlighting recent advances in our AIM injectable program demonstrating the ability to generate broad polyclonal T cell responses from memory and naive populations, as well as the synergistic benefit of a novel IO AIM ACT combination in the oncology setting, have been selected for presentation at SITC 2023," said Kristi Jones, Chief Executive Officer of NexImmune. "These abstracts showcase the continued advancement of our platform and its therapeutic potential in cancer, autoimmune and infectious diseases."
Poster Presentation Details:
Title: Efficacy of injectable antigen presenting nanoparticles (AIM INJ), in solid tumor models
Abstract Number: 1139
Category: Poster Presentation
Authors: Haiyun Liu, Duong Nguyen, Durgadas Cherukaraveedu, Adam Parks, Bryan Hahn, Daniel Dembrow, Sojung Kim, Jack Ragheb, Aniket Wadajkar, Mathias Oelke
Date & Time: Friday, Nov. 3, 2023 9 a.m. – 7 p.m. Exhibit Hall A
Title: Enhancement of bispecific T Cell engagers (bispecific TCE) killing potency in AML with NexImmune Artificial Immune Modulation (AIM) Adoptive Cell Therapy (ACT) T cells
Abstract #: 395
Category: Poster Presentation
Authors: Ruipeng Wang, Mathias Oelke, Shweta Jain, Sojung Kim, Jack ...